ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY
March 12, 2024 07:30 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY Companies to combine proprietary...
First Product Incorporating Arecor’s Arestat Technology, At220, Launched in Europe
November 17, 2023 02:00 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) FIRST PRODUCT INCORPORATING ARECOR’S ARESTAT TECHNOLOGY, AT220, LAUNCHED IN EUROPE First commercial sale triggers milestone payment and future...
Arecor: Business Update
July 20, 2023 07:00 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Strong pipeline of revenue-generating collaborations with major pharmaceutical and biotech companies with further deals anticipated...
Headline results from Phase I clinical trial of ultra-rapid acting insulin candidate AT247 demonstrate significantly accelerated insulin absorption and early exposure compared to gold standard insulins NovoLog® and Fiasp®
October 11, 2022 07:00 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor”, the “Company” or the “Group”) HEADLINE RESULTS FROM PHASE I CLINICAL TRIAL OF ULTRA-RAPID ACTING INSULIN CANDIDATE AT247 DEMONSTRATE SIGNIFICANTLY ACCELERATED...
BUSINESS UPDATE
July 14, 2022 07:00 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Pipeline for future revenue generating partnered collaborations is strong with further deals anticipated in H2 and beyondKey data for...
ARECOR TO HOST KOL WEBINAR ON THE NEED FOR CONCENTRATED AND RAPID ACTING INSULIN TREATMENTS IN DIABETES CARE
May 18, 2022 07:00 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) ARECOR TO HOST KOL WEBINAR ON THE NEED FOR CONCENTRATED AND RAPID ACTING INSULIN TREATMENTS IN DIABETES CARE Cambridge, UK, 18 May 2022: Arecor...
ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING
April 28, 2022 07:00 ET
|
Arecor Therapeutics plc
ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING Demonstrates best-in-class potential for effective...
Arecor Announces Oral Presentation at Attd 2022 of Phase i Clinical Trial of At278 Ultra-Concentrated Ultra-Rapid Acting Insulin for Diabetes
April 12, 2022 07:00 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) ARECOR ANNOUNCES ORAL PRESENTATION AT ATTD 2022 OF PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES ...
ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS
March 23, 2022 08:00 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS Further strengthens the Company’s extensive patent portfolio protecting its...
BUSINESS UPDATE
January 20, 2022 07:01 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor”, the “Company” or the “Group”) BUSINESS UPDATEMomentum continues across partnered and proprietary portfolio Cambridge, UK, 20 January 2022: Arecor Therapeutics plc...